Navigation Links
Bionovo Announces Third Quarter 2009 Highlights and Financial Results
Date:11/5/2009

EMERYVILLE, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI), a drug discovery and development company focused on the unmet needs in women's health and oncology, today announced third quarter highlights and financial results for the three months ended September 30, 2009.

Subsequent to the end of the quarter, in October 2009, Bionovo successfully completed a public offering and issued approximately 31 million shares of common stock together with approximately 29 million warrants. The net proceeds to the Company were approximately $17.7 million. The Company intends to use these proceeds to conduct a Phase 3 trial of Menerba, its lead product candidate for the treatment of menopausal vasomotor symptoms.

"The third quarter was an extremely productive quarter for Bionovo," stated Isaac Cohen, Bionovo's Chairman and Chief Executive Officer. "Not only did we publish and present a considerable amount of scientific data and make significant progress in the Menerba manufacturing and quality control process, but we also completed an important financing that sets the stage for the next chapter in the history of Bionovo. This financing provides us with the necessary funds to conclude our preparation for the FDA submission and conduct the first of two pivotal clinical trials for Menerba. This is an exciting time at Bionovo, and we eagerly anticipate the accomplishment of important milestones in the upcoming quarters."

Third Quarter 2009 Company Highlights

  • During the third quarter of 2009, Bionovo completed the raw material characterization, analytical method development and pilot manufacturing process development that constitutes a large part of the Chemistry, Manufacturing and Control (CMC) specifications necessary to satisfy the FDA's requests for clarification of the Company's ma
    '/>"/>

SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2009 Financial Results on Thursday, November 5, 2009
2. Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta
3. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
4. Bionovos Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
5. Bionovo Announces First Quarter 2009 Highlights and Financial Results
6. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
7. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
8. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
9. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
10. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
11. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Neurelis, Inc. ... ("Biotie") to end the option held by Biotie to ... further development of NRL-1 (intranasal diazepam) for pediatric and ... Over the past year, Biotie has advanced the ... preparation for the pivotal clinical work required for NDA ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
(Date:7/10/2014)... 2014  Breg, Inc., a premier provider of ... FreeRunner™ knee brace with new innovations to help ... return to active lifestyles.  FreeRunner,s patent-pending design acts ... support when patients need it most, and the ... Patellofemoral issues are the most common cause ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... privately-held therapeutic device company, today announced that DEKRA and Health ... Matrix for clinical use and sale in Europe and Canada. ... resistant, and absorbable putty designed to rapidly stop bleeding when ... cut bone is a problem in many operative procedures including ...
... announces that a new market research report is available ... Deals Analysis 2011 http://www.reportlinker.com/p0180789/Medical-Equipment-Annual-Deals-Analysis-2011.html ... Summary GlobalData,s "Medical Equipment ... of data and trend analysis on mergers and acquisitions ...
Cached Medicine Technology:ORTHOCON® Receives CE Mark and Health Canada Medical Device License for HEMASORB® 2Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 2Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 3Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 4Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 5Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 6Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 7Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 8Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 9Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 10Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 11Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 12Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 13Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 14Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 15Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 16
(Date:7/14/2014)... 14, 2014 EnergyFirst, manufacturer ... company Permalean for its great products, thriving ... Permalean, which markets its products as Jim’s Permalean Protein ... part of EnergyFirst’s lineup of nutritional products. The ... the coming year. , Founded in 1999, Permalean’s products ...
(Date:7/14/2014)... New research and analysis from the national ... examines toxic ingredients in tampons, a product used ... chemicals that may be found in the product’s absorptive ... put women’s health at risk. , According to ... , the potential impact of toxic chemical exposure from ...
(Date:7/13/2014)... FORT LEE, N.J. – Authors Leonard I. ... the science of tooth implants in their book ... describes recent advances and techniques in the world of dentistry ... who have lost all of their natural teeth. , Dr. ... subperiosteal implant in 1940. It was a mesh frame ...
(Date:7/13/2014)... 2014 MED-Ed Facilities is seeking proposals ... conference, April 7+8 in Boston at the Seaport Hotel. ... recent event. Presentations by individuals or teams are welcome. ... the types of sessions that were presented last year, ... proposal today! , Conference Director, The successful planning ...
(Date:7/13/2014)... Worldwide ladies are extremely responsive to Angeldress.co.uk’s pink ... approach and has created a lot of new items ... choices that responded directly to customers’ demands. , ... apparels. The company’s pink bridesmaid dresses come in many ... create the best products for customers from around the ...
Breaking Medicine News(10 mins):Health News:EnergyFirst Acquires Permalean - Manufacturer of All Natural Protein Bars and Powders 2Health News:EnergyFirst Acquires Permalean - Manufacturer of All Natural Protein Bars and Powders 3Health News:New Patent Analysis Shows Toxic Risk From Tampons 2Health News:New Patent Analysis Shows Toxic Risk From Tampons 3Health News:New Patent Analysis Shows Toxic Risk From Tampons 4Health News:New Patent Analysis Shows Toxic Risk From Tampons 5Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 2Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 3Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 4Health News:MED-Ed Facilities Conference Call for Speakers Open 2Health News:Angeldress.co.uk Announces Summer Sale For Pink And Red Bridesmaid Dresses; The Current Discount Is Up To 80% Off 2
... you think. Low doses of radiation have been found to ... not uncommon for children who suffer from medulloblastoma to undergo ... in affecting IQ and reading skills of younger children rather ... has been found that the greatest rates of decline in ...
... has claimed at least 20 lives in the past two ... is already present in the neighboring Indian state of UP ... caused 10 deaths each in the townships of Tikapur and ... over 80 patients were undergoing treatment in various hospitals and ...
... that the loss of a gene called p63 accelerates the ... present in many organisms, including humans // . Drawing parallels ... is likely to play a fundamental biological role in aging-related ... researchers had devised a system for eliminating it from adult ...
... prevent infections in older people living at home, report ... segment of the supplement-taking population. //, ,Studies in ... supplements, elderly people in nursing homes were 20 per ... had fewer colds over the study period than a ...
... at Jefferson Medical College had discovered the existence of ... biomarker for conditions that lead to heart failures. Based ... a blood test to predict the onset of heart ... previously showed that an enzyme called GRK2 or beta-adrenergic ...
... become nearly twice as prevalent in high schools in the ... middle school students admit that drugs are used, kept or ... where drugs are widely available are three times more likely ... alcohol than their peers who attend drug-free schools., ,Availability ...
Cached Medicine News:Health News:Latest Research Shows That Multivitamins Might Not Prevent Infections In All Elderly 2Health News:Blood Test To Predict Heart Failures 2
... complete line of enteric disease ... and monoclonal/polyclonal antibody-based ELISA tests ... pathogens in fecal specimens. Our ... difficile, Entamoeba histolytica, Giardia, Cryptosporidium ...
... II test is also available with Inverness ... greatly reduces the hands-on time required to ... testing. The Fecal-Quik-Prep device is a unique ... amount of hands-on time required to prepare ...
... for autoimmune testing feature single-well ANA screen ... specific reflex tests including dsDNA, and 6 ... SS-B (La), Scl-70 and Jo-1. In addition, ... line of products for Cardiolipins (IgA, IgG, ...
... Our ELISA products for autoimmune testing ... ELISAs, as well as specific reflex tests ... Sm, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 ... family includes a full line of products ...
Medicine Products: